Xiumei Zhao1, Yi-Jue Zhao1, Qi Lin1, Litian Yu1, Zhigang Liu1, Holly Lindsay1, Mari Kogiso1, Pulivarthi Rao1, Xiao-Nan Li1, Xinyan Lu1. 1. Laboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).
Abstract
BACKGROUND: New therapeutic targets are needed to eliminate cancer stem cells (CSCs). We hypothesize that direct comparison of paired CSCs and nonstem tumor cells (NSTCs) will facilitate identification of primary "driver" chromosomal aberrations that can serve as diagnostic markers and/or therapeutic targets. METHODS: We applied spectral karyotyping and G-banding to matched pairs of neurospheres (CSC-enriched cultures) and fetal bovine serum-based monolayer cultures (enriched with NSTCs) from 16 patient-derived orthotopic xenograft mouse models, including 9 medulloblastomas (MBs) and 7 high-grade gliomas (HGGs), followed by direct comparison of their numerical and structural abnormalities. RESULTS: Chromosomal aberrations were detected in neurospheres of all 16 models, and 82.0% numerical and 82.4% structural abnormalities were maintained in their matching monolayer cultures. Among the shared abnormalities, recurrent clonal changes were identified including gain of chromosomes 18 and 7 and loss of chromosome 10/10q (5/16 models), isochromosome 17q in 2 MBs, and a new breakpoint of 13q14 in 3 HGGs. Chromothripsis-like evidence was also observed in 3 HGG pairs. Additionally, we noted 20 numerical and 15 structural aberrations that were lost from the neurospheres and found 26 numerical and 23 structural aberrations that were only present in the NSTCs. Compared with MBs, the neurosphere karyotypes of HGG were more complex, with fewer chromosomal aberrations preserved in their matching NSTCs. CONCLUSION: Self-renewing CSCs in MBs and pediatric HGGs harbor recurrent numerical and structural aberrations that were maintained in the matching monolayer cultures. These primary chromosomal changes may represent new markers for anti-CSC therapies.
BACKGROUND: New therapeutic targets are needed to eliminate cancer stem cells (CSCs). We hypothesize that direct comparison of paired CSCs and nonstem tumor cells (NSTCs) will facilitate identification of primary "driver" chromosomal aberrations that can serve as diagnostic markers and/or therapeutic targets. METHODS: We applied spectral karyotyping and G-banding to matched pairs of neurospheres (CSC-enriched cultures) and fetal bovine serum-based monolayer cultures (enriched with NSTCs) from 16 patient-derived orthotopic xenograft mouse models, including 9 medulloblastomas (MBs) and 7 high-grade gliomas (HGGs), followed by direct comparison of their numerical and structural abnormalities. RESULTS: Chromosomal aberrations were detected in neurospheres of all 16 models, and 82.0% numerical and 82.4% structural abnormalities were maintained in their matching monolayer cultures. Among the shared abnormalities, recurrent clonal changes were identified including gain of chromosomes 18 and 7 and loss of chromosome 10/10q (5/16 models), isochromosome 17q in 2 MBs, and a new breakpoint of 13q14 in 3 HGGs. Chromothripsis-like evidence was also observed in 3 HGG pairs. Additionally, we noted 20 numerical and 15 structural aberrations that were lost from the neurospheres and found 26 numerical and 23 structural aberrations that were only present in the NSTCs. Compared with MBs, the neurosphere karyotypes of HGG were more complex, with fewer chromosomal aberrations preserved in their matching NSTCs. CONCLUSION: Self-renewing CSCs in MBs and pediatric HGGs harbor recurrent numerical and structural aberrations that were maintained in the matching monolayer cultures. These primary chromosomal changes may represent new markers for anti-CSC therapies.
Authors: David W Ellison; James Dalton; Mehmet Kocak; Sarah Leigh Nicholson; Charles Fraga; Geoff Neale; Anna M Kenney; Dan J Brat; Arie Perry; William H Yong; Roger E Taylor; Simon Bailey; Steven C Clifford; Richard J Gilbertson Journal: Acta Neuropathol Date: 2011-01-26 Impact factor: 17.088
Authors: C Lopez-Gines; M Cerda-Nicolas; R Gil-Benso; A Pellin; J A Lopez-Guerrero; R Callaghan; R Benito; P Roldan; J Piquer; J Llacer; J Barbera Journal: Clin Neuropathol Date: 2005 Sep-Oct Impact factor: 1.368
Authors: Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger Journal: Int J Cancer Date: 2008-02-15 Impact factor: 7.396
Authors: Zhigang Liu; Xiumei Zhao; Hua Mao; Patricia A Baxter; Yulun Huang; Litian Yu; Lalita Wadhwa; Jack M Su; Adekunle Adesina; Lazlo Perlaky; Mary Hurwitz; Neeraja Idamakanti; Seshidhar Reddy Police; Paul L Hallenbeck; Richard L Hurwitz; Ching C Lau; Murali Chintagumpala; Susan M Blaney; Xiao-Nan Li Journal: Neuro Oncol Date: 2013-05-07 Impact factor: 12.300
Authors: Mari Kogiso; Lin Qi; Frank K Braun; Sarah G Injac; Linna Zhang; Yuchen Du; Huiyuan Zhang; Frank Y Lin; Sibo Zhao; Holly Lindsay; Jack M Su; Patricia A Baxter; Adekunle M Adesina; Debra Liao; Mark G Qian; Stacey Berg; Jodi A Muscal; Xiao-Nan Li Journal: Clin Cancer Res Date: 2018-02-20 Impact factor: 12.531
Authors: Yulun Huang; Lin Qi; Mari Kogiso; Yuchen Du; Frank K Braun; Huiyuan Zhang; L Frank Huang; Sophie Xiao; Wan-Yee Teo; Holly Lindsay; Sibo Zhao; Patricia Baxter; Jack M F Su; Adekunle Adesina; Jianhua Yang; Sebastian Brabetz; Marcel Kool; Stefan M Pfister; Murali Chintagumpala; Laszlo Perlaky; Zhong Wang; Youxin Zhou; Tsz-Kwong Man; Xiao-Nan Li Journal: Adv Sci (Weinh) Date: 2021-11-01 Impact factor: 16.806